文献速递淋巴瘤造血干细胞移植与细胞治疗

减低强度预处理方案类型对经典霍奇金淋巴瘤异基因造血细胞移植结局的影响

Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2020-04-21

该研究分析2008至2016年间492例接受HLA相合同胞或无关供者异基因造血细胞移植的经典霍奇金淋巴瘤成人患者,比较氟达拉滨/白消安、氟达拉滨/美法仑140或氟达拉滨/环磷酰胺三种减低强度预处理方案。多因素回归分析显示各方案在非复发死亡、复发/进展和无进展生存方面无显著差异;氟达拉滨/环磷酰胺在移植后11个月内死亡风险降低,但超过11个月后死亡风险显著升高。

要点

  • 三种减低强度预处理方案在非复发死亡、复发/进展和无进展生存方面无显著差异。
  • 氟达拉滨/环磷酰胺在移植后11个月内死亡风险降低(HR=0.28),但超过11个月后死亡风险显著升高(HR=2.46)。
  • 四种调整后总生存率相似:氟达拉滨/白消安62%、氟达拉滨/美法仑140为59%、氟达拉滨/环磷酰胺55%。

核心结论

  • 减低强度预处理方案选择不影响经典霍奇金淋巴瘤异基因造血细胞移植的复发、非复发死亡或无进展生存风险。
  • 氟达拉滨/白消安与氟达拉滨/美法仑140之间未见总生存获益;氟达拉滨/环磷酰胺与移植后超过11个月死亡风险显著升高相关,可能源于晚期非复发死亡事件。

研究设计与样本

  • 回顾性分析2008年至2016年间492例接受HLA相合同胞或无关供者异基因造血细胞移植的经典霍奇金淋巴瘤成人患者。
  • 预处理方案为氟达拉滨/白消安、氟达拉滨/美法仑140或氟达拉滨/环磷酰胺的减低强度预处理。
  • 采用多因素回归分析,显著性水平为<0.01。

主要发现

  • 各方案间非复发死亡风险无显著差异(P=0.54)。
  • 各方案间复发/进展风险无显著差异(P=0.02),未达预设显著性水平0.01。
  • 各方案间无进展生存无显著差异(P=0.14)。
  • 氟达拉滨/环磷酰胺与移植后11个月内死亡风险降低相关(HR=0.28;95%CI=0.10-0.73;P=0.009)。
  • 氟达拉滨/环磷酰胺与移植后超过11个月死亡风险显著升高相关(HR=2.46;95%CI=1.32-4.61;P=0.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reduced-intensity conditioning (RIC) allogeneic haematopoietic cell transplantation (allo-HCT) is a curative option for select relapsed/refractory Hodgkin lymphoma (HL) patients; however, there are sparse data to support superiority of any particular conditioning regimen. We analyzed 492 adult patients undergoing human leucocyte antigen (HLA)-matched sibling or unrelated donor allo-HCT for HL between 2008 and 2016, utilizing RIC with either fludarabine/busulfan (Flu/Bu), fludarabine/melphalan (Flu/Mel140) or fludarabine/cyclophosphamide (Flu/Cy). Multivariable regression analysis was performed using a significance level of <0·01. There were no significant differences between regimens in risk for non-relapse mortality (NRM) (P = 0·54), relapse/progression (P = 0·02) or progression-free survival (PFS) (P = 0·14). Flu/Cy conditioning was associated with decreased risk of mortality in the first 11 months after allo-HCT (HR = 0·28; 95% CI = 0·10-0·73; P = 0·009), but beyond 11 months post allo-HCT it was associated with a significantly higher risk of mortality, (HR = 2·46; 95% CI = 0·1.32-4·61; P = 0·005). Four-year adjusted overall survival (OS) was similar across regimens at 62% for Flu/Bu, 59% for Flu/Mel140 and 55% for Flu/Cy (P = 0·64), respectively. These data confirm the choice of RIC for allo-HCT in HL does not influence risk of relapse, NRM or PFS. Although no OS benefit was seen between Flu/Bu and Flu/Mel 140; Flu/Cy was associated with a significantly higher risk of mortality beyond 11 months from allo-HCT (possibly due to late NRM events).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ahmed S, Ghosh N, Ahn KW, et al. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020. PMID: 32314807. doi:10.1111/bjh.16664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。